Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Expenditures (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Capital Expenditures data on record, last reported at $2.4 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 189.08% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $8.9 million, up 12557.14%, while the annual FY2025 figure was $8.9 million, 12557.14% up from the prior year.
  • Capital Expenditures reached $2.4 million in Q4 2025 per PTCT's latest filing, down from $3.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $22.8 million in Q3 2023 and bottomed at -$10.2 million in Q2 2023.
  • Average Capital Expenditures over 5 years is $4.9 million, with a median of $5.6 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: plummeted 217.63% in 2023, then soared 559.96% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $8.7 million in 2021, then dropped by 1.19% to $8.6 million in 2022, then crashed by 35.44% to $5.6 million in 2023, then crashed by 147.88% to -$2.7 million in 2024, then skyrocketed by 189.08% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $2.4 million in Q4 2025, $3.4 million in Q3 2025, and $1.3 million in Q2 2025.